ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO814

Labile Plasma Iron for the Early Detection of Iron Overload in ESRD

Session Information

Category: Dialysis

  • 605 Dialysis: Anemia and Iron Metabolism


  • Benaya, Alon, shaare zedek, Jerusalem, Israel
  • Slotki, Itzchak N., Share Zedek Medical Center, Jerusalem, Israel
  • Shavit, Linda, Shaare Zedek Medical Center, Jerusalem, Israel
  • Malyszko, Jolanta, Medical University, Bialystok, Poland

The increased usage of intravenous iron (IVI) in hemodialysis patients during recent years has led to increasing concern over the potential development of iron overload (IO). Current methods for detecting iron overload, transferrin saturation (TSAT) and serum ferritin are neither sensitive nor specific. Labile plasma iron (LPI) represents a component of non-transferrin bound iron that is both redox active and chelatable and may be a more accurate indicator of impending iron overload. We studied whether LPI measured using the FeROS LPI detecting system (Aferrix) can serve as an early indicator of impending IO in hemodialysis patients.


Chronic hemodialysis patients from two medical centers in Israel and Poland who received IVI were included. Demographic data, cause of ESRD, comorbidities, medications and the following laboratory parameters were recorded: Hb, serum iron, transferrin, TSAT, ferritin. LPI was measured before and 48 hours after a single IV administration of either iron sucrose 100 mg, iron gluconate 62.5 mg, iron (III)-hydroxide dextran complex 100 mg. A test result of 0.6 units of LPI or more indicated a potential for iron-mediated production of reactive oxygen species in the sample.


111 hemodialysis patients, aged 64 ± 15, were included in the study. 90 patients received iron sucrose, 14 iron gluconate and 7 iron dextran at mean monthly doses of 233 ± 133 mg; LPI was negative in all patients prior to IVI, but became positive post administration in 4 patients, all of whom received iron sucrose. Three of these were diabetic, had TSAT <30% and ferritin <360 ng/ml and received monthly iron doses of 400-500 mg.


Doses of IVI routinely used in chronic hemodialysis patients appear to be safe. However, higher monthly doses may be associated with detectable LPI post administration, even in the absence of currently used laboratory parameters of IO.